THE ABSOLUTE LYMPHOCYTE COUNT AS INDEPENDENT PARAMETER MAY PREDICT PROGNOSIS OF FOLLICULAR LYMPHOMA PATIENTS
(Abstract release date: 05/19/16)
EHA Library. Jelicic J. 06/09/16; 134765; PB1865
Dr. Jelena Jelicic
Contributions
Contributions
Abstract
Abstract: PB1865
Type: Publication Only
Background
The role of absolute lymphocyte count (ALC), absolute monocyte count (AMC) and lymphocyte to monocyte ratio (LMR) in follicular lymphoma (FL) as potential surrogate markers of gene expression profiling analysis has been investigated with consequently reported contradictory data.
Aims
The aim of this study was to evaluate the role of clinical and laboratory parameters, including ALC, AMC and LMR, on the overall survival (OS) and event free survival (EFS).
Methods
A total of 185 patients (106 females/79 males) with median age of 55 years (range 30-88 years) were analyzed. Majority of patients (87.6%) were in advanced Ann Arbor clinical stage (III-V), while 8.1% had leukemic phase of the disease. Bone marrow infiltration had 61.1% patients and histopathological grade 3 of disease had 25.4% of them. Low FLIPI (Follicular Lymphoma International Prognostic Index) had 22.2% of patients, intermediate 28.1% and high 44.3%. Pre-therapy median ALC was 1.83x109/L (range 0.10-123.9x109/l), AMC 0.52x109/l (range 0.06-12.39x109/l) and LMR 4.0 (range 0.04-97.0x109/l). Cut off values were set on 1.1x109/l, 0.63x109/l and 4.7x109/l for ALC, AMC and LMR, respectively, according to the previously published data. All patients were treated with immunochemotherapy.
Results
Complete remission (CR) was achieved in 64.9% of patients, partial remission (PR) in 27.0% and 8.1% of patients had primary resistant disease. The disease relapse was verified in 39.5%. The following variables didn't influence neither OS nor EFS: gender, Ann Arbor disease stage, presence of B symptoms, bulky disease, and leukemic phase of disease. However, the FLIPI had significant impact on the OS (Log Rank=11.75, p=0.003) and EFS (Log Rank=9.14, p=0.01). Furthermore, the patients with lymphoma grade 1-3 had superior OS (Log Rank=10.70, p=0.001) and EFS (Log Rank=6.89, p=0.009) compared to the patients with grade 3. The patients with ALC≥1.1x109/l had better OS (Log Rank=4.135, p=0.042) and EFS (Log Rank=3.9, p=0.049) compared to those with lower ALC values. However, AMC and LMR were not in correlation with the outcome. Multivariate Cox regression analysis among FLIPI, lymphoma grade and ALC, has sorted over lymphoma grade as the most important parameter that influenced OS (HR=6.57, 95% CI 1.49-6.58, p=0.003) and EFS (HR=2.56, 95% CI 1.24-5.32, p=0.011) along with the FLIPI (OS, HR=1.50, 95% CI 1.09-2.05, p=0.012; EFS, HR=1.4, 95% CI 1.03-1.92, p=0.03).
Conclusion
In FL patients ALC, as individual parameter, markedly influenced survival. Moreover, in the rituximab era FLIPI still retains prognostic significance along with the histological grade of FL illustrating biologically different course of disease.
Session topic: E-poster
Keyword(s): Clinical data, Follicular lymphoma, Prognosis
Type: Publication Only
Background
The role of absolute lymphocyte count (ALC), absolute monocyte count (AMC) and lymphocyte to monocyte ratio (LMR) in follicular lymphoma (FL) as potential surrogate markers of gene expression profiling analysis has been investigated with consequently reported contradictory data.
Aims
The aim of this study was to evaluate the role of clinical and laboratory parameters, including ALC, AMC and LMR, on the overall survival (OS) and event free survival (EFS).
Methods
A total of 185 patients (106 females/79 males) with median age of 55 years (range 30-88 years) were analyzed. Majority of patients (87.6%) were in advanced Ann Arbor clinical stage (III-V), while 8.1% had leukemic phase of the disease. Bone marrow infiltration had 61.1% patients and histopathological grade 3 of disease had 25.4% of them. Low FLIPI (Follicular Lymphoma International Prognostic Index) had 22.2% of patients, intermediate 28.1% and high 44.3%. Pre-therapy median ALC was 1.83x109/L (range 0.10-123.9x109/l), AMC 0.52x109/l (range 0.06-12.39x109/l) and LMR 4.0 (range 0.04-97.0x109/l). Cut off values were set on 1.1x109/l, 0.63x109/l and 4.7x109/l for ALC, AMC and LMR, respectively, according to the previously published data. All patients were treated with immunochemotherapy.
Results
Complete remission (CR) was achieved in 64.9% of patients, partial remission (PR) in 27.0% and 8.1% of patients had primary resistant disease. The disease relapse was verified in 39.5%. The following variables didn't influence neither OS nor EFS: gender, Ann Arbor disease stage, presence of B symptoms, bulky disease, and leukemic phase of disease. However, the FLIPI had significant impact on the OS (Log Rank=11.75, p=0.003) and EFS (Log Rank=9.14, p=0.01). Furthermore, the patients with lymphoma grade 1-3 had superior OS (Log Rank=10.70, p=0.001) and EFS (Log Rank=6.89, p=0.009) compared to the patients with grade 3. The patients with ALC≥1.1x109/l had better OS (Log Rank=4.135, p=0.042) and EFS (Log Rank=3.9, p=0.049) compared to those with lower ALC values. However, AMC and LMR were not in correlation with the outcome. Multivariate Cox regression analysis among FLIPI, lymphoma grade and ALC, has sorted over lymphoma grade as the most important parameter that influenced OS (HR=6.57, 95% CI 1.49-6.58, p=0.003) and EFS (HR=2.56, 95% CI 1.24-5.32, p=0.011) along with the FLIPI (OS, HR=1.50, 95% CI 1.09-2.05, p=0.012; EFS, HR=1.4, 95% CI 1.03-1.92, p=0.03).
Conclusion
In FL patients ALC, as individual parameter, markedly influenced survival. Moreover, in the rituximab era FLIPI still retains prognostic significance along with the histological grade of FL illustrating biologically different course of disease.
Session topic: E-poster
Keyword(s): Clinical data, Follicular lymphoma, Prognosis
Abstract: PB1865
Type: Publication Only
Background
The role of absolute lymphocyte count (ALC), absolute monocyte count (AMC) and lymphocyte to monocyte ratio (LMR) in follicular lymphoma (FL) as potential surrogate markers of gene expression profiling analysis has been investigated with consequently reported contradictory data.
Aims
The aim of this study was to evaluate the role of clinical and laboratory parameters, including ALC, AMC and LMR, on the overall survival (OS) and event free survival (EFS).
Methods
A total of 185 patients (106 females/79 males) with median age of 55 years (range 30-88 years) were analyzed. Majority of patients (87.6%) were in advanced Ann Arbor clinical stage (III-V), while 8.1% had leukemic phase of the disease. Bone marrow infiltration had 61.1% patients and histopathological grade 3 of disease had 25.4% of them. Low FLIPI (Follicular Lymphoma International Prognostic Index) had 22.2% of patients, intermediate 28.1% and high 44.3%. Pre-therapy median ALC was 1.83x109/L (range 0.10-123.9x109/l), AMC 0.52x109/l (range 0.06-12.39x109/l) and LMR 4.0 (range 0.04-97.0x109/l). Cut off values were set on 1.1x109/l, 0.63x109/l and 4.7x109/l for ALC, AMC and LMR, respectively, according to the previously published data. All patients were treated with immunochemotherapy.
Results
Complete remission (CR) was achieved in 64.9% of patients, partial remission (PR) in 27.0% and 8.1% of patients had primary resistant disease. The disease relapse was verified in 39.5%. The following variables didn't influence neither OS nor EFS: gender, Ann Arbor disease stage, presence of B symptoms, bulky disease, and leukemic phase of disease. However, the FLIPI had significant impact on the OS (Log Rank=11.75, p=0.003) and EFS (Log Rank=9.14, p=0.01). Furthermore, the patients with lymphoma grade 1-3 had superior OS (Log Rank=10.70, p=0.001) and EFS (Log Rank=6.89, p=0.009) compared to the patients with grade 3. The patients with ALC≥1.1x109/l had better OS (Log Rank=4.135, p=0.042) and EFS (Log Rank=3.9, p=0.049) compared to those with lower ALC values. However, AMC and LMR were not in correlation with the outcome. Multivariate Cox regression analysis among FLIPI, lymphoma grade and ALC, has sorted over lymphoma grade as the most important parameter that influenced OS (HR=6.57, 95% CI 1.49-6.58, p=0.003) and EFS (HR=2.56, 95% CI 1.24-5.32, p=0.011) along with the FLIPI (OS, HR=1.50, 95% CI 1.09-2.05, p=0.012; EFS, HR=1.4, 95% CI 1.03-1.92, p=0.03).
Conclusion
In FL patients ALC, as individual parameter, markedly influenced survival. Moreover, in the rituximab era FLIPI still retains prognostic significance along with the histological grade of FL illustrating biologically different course of disease.
Session topic: E-poster
Keyword(s): Clinical data, Follicular lymphoma, Prognosis
Type: Publication Only
Background
The role of absolute lymphocyte count (ALC), absolute monocyte count (AMC) and lymphocyte to monocyte ratio (LMR) in follicular lymphoma (FL) as potential surrogate markers of gene expression profiling analysis has been investigated with consequently reported contradictory data.
Aims
The aim of this study was to evaluate the role of clinical and laboratory parameters, including ALC, AMC and LMR, on the overall survival (OS) and event free survival (EFS).
Methods
A total of 185 patients (106 females/79 males) with median age of 55 years (range 30-88 years) were analyzed. Majority of patients (87.6%) were in advanced Ann Arbor clinical stage (III-V), while 8.1% had leukemic phase of the disease. Bone marrow infiltration had 61.1% patients and histopathological grade 3 of disease had 25.4% of them. Low FLIPI (Follicular Lymphoma International Prognostic Index) had 22.2% of patients, intermediate 28.1% and high 44.3%. Pre-therapy median ALC was 1.83x109/L (range 0.10-123.9x109/l), AMC 0.52x109/l (range 0.06-12.39x109/l) and LMR 4.0 (range 0.04-97.0x109/l). Cut off values were set on 1.1x109/l, 0.63x109/l and 4.7x109/l for ALC, AMC and LMR, respectively, according to the previously published data. All patients were treated with immunochemotherapy.
Results
Complete remission (CR) was achieved in 64.9% of patients, partial remission (PR) in 27.0% and 8.1% of patients had primary resistant disease. The disease relapse was verified in 39.5%. The following variables didn't influence neither OS nor EFS: gender, Ann Arbor disease stage, presence of B symptoms, bulky disease, and leukemic phase of disease. However, the FLIPI had significant impact on the OS (Log Rank=11.75, p=0.003) and EFS (Log Rank=9.14, p=0.01). Furthermore, the patients with lymphoma grade 1-3 had superior OS (Log Rank=10.70, p=0.001) and EFS (Log Rank=6.89, p=0.009) compared to the patients with grade 3. The patients with ALC≥1.1x109/l had better OS (Log Rank=4.135, p=0.042) and EFS (Log Rank=3.9, p=0.049) compared to those with lower ALC values. However, AMC and LMR were not in correlation with the outcome. Multivariate Cox regression analysis among FLIPI, lymphoma grade and ALC, has sorted over lymphoma grade as the most important parameter that influenced OS (HR=6.57, 95% CI 1.49-6.58, p=0.003) and EFS (HR=2.56, 95% CI 1.24-5.32, p=0.011) along with the FLIPI (OS, HR=1.50, 95% CI 1.09-2.05, p=0.012; EFS, HR=1.4, 95% CI 1.03-1.92, p=0.03).
Conclusion
In FL patients ALC, as individual parameter, markedly influenced survival. Moreover, in the rituximab era FLIPI still retains prognostic significance along with the histological grade of FL illustrating biologically different course of disease.
Session topic: E-poster
Keyword(s): Clinical data, Follicular lymphoma, Prognosis
{{ help_message }}
{{filter}}